SCHEMBL23129128

SCHEMBL23129128

c1ccc2cc(-c3nc(-n4c5ccc6ccccc6c5c5c6c7ccccc7c7ccccc7c6ccc54)nc4c3oc3ccccc34)ccc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
NPC1 O15118 1/20 0.36
CYP2C9 P11712 1/20 0.36
RAB9A P51151 1/20 0.36
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TSHR P16473 3/20 0.32
MAPT P10636 5/20 0.31
LMNA P02545 3/20 0.31
CREBBP Q92793 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ABCG2 Q9UNQ0 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
USP2 O75604 1/20 0.31
KMT2A Q03164 4/20 0.31
MEN1 O00255 3/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23983604 0.93 TDP1 (0.32) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23129089 0.93 NPC1 (0.35) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23129408 0.92 NPC1 (0.33) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23129171 0.92 NPC1 (0.35) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23129092 0.91 TSHR (0.38) CYP1A2CYP2C19CYP2C9TDP1L3MBTL1
SCHEMBL22211871 0.90 NPC1 (0.35) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL21475035 0.89 NPC1 (0.36) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23129696 0.89 NPC1 (0.31) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL22989054 0.89 CYP1A2 (0.38) CYP1A2CYP2C19NPC1CYP2C9RAB9A
SCHEMBL23984002 0.89 TSHR (0.34) CYP1A2CYP2C19NPC1CYP2C9RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2024-01-02 US disclosed
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2024-01-02 US disclosed
US-20210340159-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG CHEM, LTD. (KR) 2021-11-04 US disclosed
EP-3795569-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME LG CHEM, LTD. (KR) 2021-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340159-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME NR4A1, CYP1A1, ARNT CYP1A2 36/4885CYP2C19 48/4885NPC1 2374/4885
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same NR4A1, CYP1A1, ARNT CYP1A2 36/4885CYP2C19 48/4885NPC1 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.